EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Subscribe To Our Newsletter & Stay Updated
